IntelliGenome Appoints ILEX South Africa as Exclusive Distributor for CRISPR-TB

IntelliGenome, Inc., a biotechnology firm specializing in CRISPR-based molecular diagnostics, has appointed ILEX South Africa (Pty) Ltd. as its exclusive distributor for CRISPR-TB® in South Africa. The country is recognized globally as a leader in tuberculosis research and clinical innovation, making the potential impact of CRISPR-TB on tuberculosis diagnostics significant.

CRISPR-TB is a proprietary molecular assay developed by IntelliGenome, designed to detect Mycobacterium tuberculosis complex cell-free DNA from blood samples, representing a new method for tuberculosis diagnosis.

This partnership aligns with South Africa's National TB Recovery Plan and National Strategic Plan, which focus on identifying unreported TB cases, enhancing access to advanced molecular diagnostics, improving treatment outcomes, and bolstering prevention efforts. Kurt Wehrle, Vice President of Partnerships & Strategic Alliances at IntelliGenome, emphasized, "South Africa has consistently led the world in tuberculosis research and innovation. Together with ILEX, we look forward to supporting South Africa's efforts to improve TB detection and expand access to advanced molecular diagnostics."

ILEX will spearhead the introduction of CRISPR-TB by overseeing regulatory registration, market development, technical support, and scientific collaboration with TB researchers and healthcare institutions. Shameera August, Chief Executive Officer of ILEX South Africa, remarked, "We are pleased to partner with IntelliGenome to help advance blood-based tuberculosis diagnostics in South Africa. We look forward to working with clinicians, researchers, and healthcare institutions to expand access to CRISPR-TB throughout South Africa."

IntelliGenome is focused on the creation and commercialization of innovative CRISPR-based diagnostic technologies, with the CRISPR-TB platform being assessed globally in partnerships with clinical, academic, and public health entities.

ILEX South Africa, established in 1992, is a prominent provider of in vitro diagnostics and laboratory solutions across Africa. With its headquarters in Johannesburg and a reach extending into 16 additional African countries, ILEX collaborates with healthcare institutions, blood services, clinical laboratories, and research organizations to deliver advanced diagnostic technologies along with robust regulatory and technical support.